Nocopi Technologies, Inc. (NNUP) Q3 Revenue Rose 763% to $3.3M

Nocopi Technologies (NNUP) reported Q3 2026 revenue of $3.3M, up 763% YoY, with net income of $1.4M versus a $27K loss a year earlier. Gross margin improved to 66% from 46%. The growth follows the company's recent acquisition of Polymeric.

Original reporting
Published Nov 12, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nocopi Technologies, Inc. (NNUP) Q3 Revenue Rose 763% to $3.3M — source image
Decision brief

The 30-second read

$NNUPBullishLow
01

Why it matters

The earnings surprise could trigger short‑term buying interest, but the stock's thin float may lead to volatility.

02

Market read

First earnings release after acquisition; significant revenue growth and profitability for a micro‑cap.

03

What to watch

Liquidity constraints and limited analyst coverage could cap price appreciation.

Relevance 6/10Novelty 6/10Timing: post‑earnings release today

Background

Nocopi Technologies recently completed an acquisition and is reporting its first full‑quarter results post‑deal.

Company-level read

Ticker impact

$NNUPBullishMedium confidence
Context

Q3 2026 revenue rose 763% to $3.3M and net income turned positive at $1.4M, marking the first earnings release after the acquisition.

Expected impact

likely upward pressure as investors price in rapid revenue growth and profitability.

Evidence & confidence

The dramatic revenue increase and profit swing are new data points that could attract speculative buying in a thinly traded stock.

Market effects

Shows potential upside for other recent acquisition targets in the AI‑hardware niche.

Limited to US micro‑cap investors; no broader regional effect.

Minimal global impact due to small company size.

Counterpoint

Rapid growth may be unsustainable; integration risks could reverse momentum.

Key entities

  • Nocopi Technologies, Inc.

    Micro‑cap AI‑hardware firm reporting Q3 2026 results.

Related articles

$NNUPMed

Nocopi Technologies Reports Third Quarter Results

NOCOPI TECHNOLOGIES INC/MD/ (NNUP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nocopi Technologies Reports Third Quarter Results KING OF PRUSSIA, PA – November 12, 2026 – Nocopi Technologies, Inc. (“Nocopi Technologies” or the “Company”; OTCQB: NNUP) today reported financial results for the quarter ended September 30, 2026. 2026 Third Quarter H

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).